Congratulations everyone. We are looking at the world's first real treatment for Phelan-McDermid syndrome (PMS). The results are somewhat better than I could have hoped for. Clinicians and caregivers scoring is very consistent, which is both confirming and exciting. The p-values are exactly where we would hope p<0.05, so this will stand up to solid scrutiny.
In my opinion, I would have to say that these results are stronger than those we saw in the Rett Ph2 results, and we all know where that went.
I believe that BP will now have eyes on NEU and if the results are similar in ANY of the other conditions that are still in PH2, then this little super star should be irresistible to Big Pharma. I can't see my plan for long term dividends coming, I see a buyout.
Wonderful news, well done to all holders.
All opinion only, of course
NEU Price at posting:
$17.14 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)